Search results
Results from the WOW.Com Content Network
Alzheimer’s Research UK said the finding was a “historic moment for dementia research”, as this is the first later-stage trial of an Alzheimer’s drug “in a generation” to successfully ...
Alzheimer’s disease is the most common cause of dementia in the UK and affects memory, thinking and other mental abilities. It is a progressive condition which means symptoms develop gradually ...
Experts have hailed the “beginning of the end” in the search for effective Alzheimer’s treatments after a new drug reduced memory decline among patients with early stages of the disease ...
Solanezumab was safely used in combination with approved Alzheimer's disease treatment, such as acetylcholinesterase inhibitors or memantine, in the clinical trials. [1] [7] [8] Aside from Alzheimer's disease, there are other amyloid beta related diseases, in which solanezumab could be used, e.g., Down syndrome or cerebral amyloid angiopathy. [9]
J147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. [1] [2] [3] [4]The approach that lead to development of the J147 drug was to screen candidate molecules for anti-aging effects, instead of targeting the amyloid plaques.
The term senile dementia of the Alzheimer type (SDAT) was used for a time to describe the condition in those over 65, with classical Alzheimer's disease being used to describe those who were younger. Eventually, the term Alzheimer's disease was formally adopted in medical nomenclature to describe individuals of all ages with a characteristic ...
The prevention of dementia involves reducing the number of risk factors for the development of dementia, and is a global health priority needing a global response. [1] [2] Initiatives include the establishment of the International Research Network on Dementia Prevention (IRNDP) [3] which aims to link researchers in this field globally, and the establishment of the Global Dementia Observatory ...
Moderate and severe traumatic brain injuries increase a risk of cognitive decline or dementia even years later by anywhere from two to four times, according to the Alzheimer’s Association. For ...